From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

No More Cipro for Gay Men with Gonorrhea

Quinolone-resistant gonorrhea has reached a tipping point among men who have sex with men.

Quinolone-resistant gonorrhea was first reported in the U.S. in 1998 (Journal Watch Jun 5 1998). By 2002, it had become common enough in California and Hawaii for the CDC to recommend against using quinolones to treat patients with gonorrhea acquired in these states (Journal Watch Dec 24 2002). The frequency of quinolone-resistant gonorrhea has now reached the same tipping point nationally among men who have sex with men (MSM).

A CDC-sponsored nationwide surveillance system annually monitors drug susceptibilities of about 5000 gonococcal isolates obtained from men with the disease at 30 STD clinics. The overall prevalence of quinolone resistance rose from 0.7% in 2001 to 2.2% in 2002 to 4.2% in 2003. Among MSM, the 2003 prevalence was 4.9% (up from 1.8% in 2002); among heterosexual men, it was 0.4%. Closer evaluation in 2003 of gonorrhea patients in STD clinics in Massachusetts and New York found that quinolone resistance was present in 5% to 10% of cases from whom cultures were taken; nearly all resistant infections were in MSM.

Comment: Quinolone treatment of gonorrhea is popular for its one-dose convenience, particularly because the recommended alternative is intramuscular ceftriaxone. However, clinicians should be aware of the unacceptably high possibility of failure in MSM. If absolutely unavoidable, quinolones should be given to MSM only if cultures are taken and patients can be recalled if treatment fails. At the time of publication, the full text of the original article was available free of charge.

— Abigail Zuger, MD

Published in Journal Watch General Medicine May 11, 2004

Citation(s):

Centers for Disease Control and Prevention (CDC). Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men -- United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 2004 Apr 30; 53:335-8.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2004. Massachusetts Medical Society. All rights reserved.